HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

← Back to guidelines

Rheumatology321 papers

Hyperuricemia, anemia, renal failure syndrome

Last edited: 4/17/2026

Overview

Hyperuricemia is characterized by elevated serum uric acid levels and is associated with various comorbidities including gout, renal failure, cardiovascular disease, and anemia. It represents a significant public health issue due to its heterogeneous clinical presentation and multifaceted pathophysiology 1 2 7 11 25.

Diagnosis

Serum Uric Acid Measurement: Primary diagnostic test, typically defined as >6.8 mg/dL 1 25.

Comprehensive Metabolic Panel: To assess renal function and identify potential renal failure 11.

Complete Blood Count (CBC): Evaluate for anemia associated with chronic disease 1 25.

Imaging: Ultrasound may be used to detect early gout or renal abnormalities in asymptomatic patients 49.

Genetic Testing: Consideration for identifying genetic risk factors influencing hyperuricemia 55 66.

Management

Urate-Lowering Therapy (ULT):

- First-Line Drugs: Allopurinol (100-300 mg/day) and febuxostat (40-80 mg/day) 13 23 45. - Alternative Agents: Febuxostat preferred in Asian patients without significant cardiovascular risk 23. - Novel Agents: Dotinurad and URAT1 inhibitors like HP501 for refractory cases 31 36 71.

Lifestyle Modifications:

- Dietary Changes: Reduced purine intake, low-fructose diet, adherence to DASH diet 16 33 50. - Weight Management: Weight reduction can lower serum urate levels 16 33. - Alcohol Reduction: Limit alcohol intake to decrease serum urate levels 31.

Cardiovascular Risk Management: Address concomitant cardiovascular risk factors 7 18.

Special Populations

Pregnancy: Limited data; monitor closely and consider conservative management 2 25.

Pediatrics: Febuxostat effective but requires careful dosing adjustments 13.

Elderly: Increased risk of renal impairment; monitor renal function closely 11 25.

Comorbidities:

- Renal Failure: Tailor ULT based on renal function; monitor closely for efficacy and safety 11 39. - Cardiovascular Disease: ULT may reduce cardiovascular risk; monitor cardiovascular events 7 47 48.

Key Recommendations

Initiate urate-lowering therapy in symptomatic hyperuricemia and consider it in asymptomatic patients with comorbidities like cardiovascular disease or renal impairment (Evidence: Moderate) 7 47 48.

Use allopurinol or febuxostat as first-line treatments, with dose adjustments based on renal function (Evidence: Strong) 13 23 45.

Implement lifestyle modifications including dietary changes and weight management to complement pharmacological therapy (Evidence: Moderate) 16 33 50.

Regularly monitor serum uric acid levels and renal function in patients with hyperuricemia, especially those with renal impairment (Evidence: Moderate) 11 39.

Evaluate and manage associated conditions such as anemia and cardiovascular risk factors concurrently (Evidence: Moderate) 1 25.

References

Showing 100 most recent of 144 indexed papers.

1 Wang J, Zeng Z, Duan W, Man Z, Wang M, Yang Z. Unraveling the heterogeneity of hyperuricemia using untargeted metabolomics and statistical modeling. Journal of pharmaceutical and biomedical analysis 2026. link 2 Zhang X, Wang W, Yang L, Sun Y, Sun H, Zhao X et al.. Targeting amino acid metabolic pathways: a novel therapeutic strategy for hyperuricemia-associated complications. Amino acids 2026. link 3 Dalbeth N, Stewart S, Gamble GD, Mihov B, Stamp LK, Haslett J et al.. Perceptions About Asymptomatic Hyperuricemia and Views About Urate-Lowering Therapy in People With Asymptomatic Hyperuricemia. Arthritis care & research 2026. link 4 Shi H, Zhu Y, Guo Q, Li J, Lv T, Wu Y et al.. Patients' knowledge influences practice via attitudes toward hyperuricaemia: a mediation analysis. Clinical rheumatology 2026. link 5 Ohashi Y, Ichihara S, Yamamoto K, Kitamura Y, Matsubara T, Beppo R et al.. Proteomic footprint of serum urate concentration and urate transporter . RMD open 2026. link 6 Billa S, Fukui S, Paudel ML, Suzuki T, Imai R, Kim Y et al.. Longitudinal Changes in Serum Urate Levels From Premenopause Through Postmenopause: Interrupted Time-Series Analyses. Arthritis & rheumatology (Hoboken, N.J.) 2026. link 7 She C, Shi L, Li Y, Qin L, Fang N, Shi K et al.. The relationship between the atherogenic index of plasma and hyperuricemia in American adults aged over 20 years: A cross-sectional study. PloS one 2026. link 8 Ghukasyan H, Pedro Navalha DD, Pérez Romero I, Prato Wolwacz MV, Ghahramanyan A, Tsing Ngan CW et al.. Reducing hyperuricemic events with SGLT2 inhibitors: An updated systematic review with meta-regression. Endocrinologia, diabetes y nutricion 2025. link 9 Sun L, Zhang M, Zhao J, Chen W, Wang G. The human gut microbiota and uric acid metabolism: genes, metabolites, and diet. Critical reviews in food science and nutrition 2025. link 10 Chen Y, Li G, Asghar A, Fang Q, Yang J, Zhong Y et al.. Bibliometric and visual assessment of research trends in the management of hyperuricemia (HUA). Clinical rheumatology 2025. link 11 Lv W, Chen H, Zhou P, Du A, Lei Y. Mechanisms Associated With Renal Injury in Hyperuricemia and Strategies for the Development of Natural Active Substances. International journal of rheumatic diseases 2025. link 12 Li Z, Gao G, Lv Y, Zhang Y, Wang H, Liu B. A Rapid Electrochemical DNA Biosensor for Serum Uric Acid Using the Pre-equilibrium Binding Mechanism. Analytical chemistry 2025. link 13 Faghihi T, Assadi F. Febuxostat, a Urate-Lowering Drug Bridging From Adults to Pediatrics; A Brief Report. Clinical therapeutics 2025. link 14 Ding H, Liang Y, Wang Y, Zhang K, Zhu M, Jing Y et al.. Effects of thyroid-stimulating hormone and sensitivity to thyroid hormones on the risk of hyperuricemia in euthyroid adults. Archives of endocrinology and metabolism 2025. link 15 Long Z, Zhao H, Yin Y, Sun Y, Shen P, Lin H et al.. Clinical outcomes and safety of Chinese herbal medicine in the treatment of hyperuricemia: A retrospective real-world study. Phytomedicine : international journal of phytotherapy and phytopharmacology 2025. link 16 Fukui S, Okada M, Shinozaki T, Suzuki T, Nakai T, Ozawa H et al.. Weight Reduction and Target Serum Urate Level: A Longitudinal Study of Annual Medical Examination. Arthritis & rheumatology (Hoboken, N.J.) 2025. link 17 Xian D, Wang W, Li H, Song G, Xu D, Zhang F et al.. Lipid accumulation product: A novel marker for gout and hyperuricemia. PloS one 2025. link 18 Zhong L, Li D, Xu F, Wu Y, Zhang Y. Higher cardiometabolic index elevates the risk of hyperuricemia in the elderly: findings from the China health and retirement longitudinal study. Annals of medicine 2025. link 19 Lu X, Liu F, Chen H, Cai H, Zhang L, Li J. Effects of WN1703 on Cardiovascular Function in Chronic Hyperuricemia Rats and Myocardial Injury Mechanism Exploration in H9C2 Cells. Journal of applied toxicology : JAT 2025. link 20 Moszczuk B, Życińska K, Mucha K. Asymptomatic Hyperuricemia: A Nephro-Rheumatological Perspective. Archivum immunologiae et therapiae experimentalis 2024. link 21 Zhang T, Liu W, Gao S. Exercise and hyperuricemia: an opinion article. Annals of medicine 2024. link 22 Chang KC, Huang SY, Tsai WH, Liu HW, Liu JS, Wu CL et al.. Dissecting the risk factors for hyperuricemia in vegetarians in Taiwan. Journal of the Chinese Medical Association : JCMA 2024. link 23 Deng JH, Lai PH, Xie LS, Qiu SS, Qiu DS, Zhang JX. Cardiovascular safety of febuxostat versus allopurinol among the Asian patients with or without gout: A systematic review and meta-analysis. Clinical and translational science 2024. link 24 Du J, Wang N, Yu D, He P, Gao Y, Tu Y et al.. Data mining-guided alleviation of hyperuricemia by Paeonia veitchii Lynch through inhibition of xanthine oxidase and regulation of renal urate transporters. Phytomedicine : international journal of phytotherapy and phytopharmacology 2024. link 25 Du L, Zong Y, Li H, Wang Q, Xie L, Yang B et al.. Hyperuricemia and its related diseases: mechanisms and advances in therapy. Signal transduction and targeted therapy 2024. link 26 Leong PY, Chen HH, Gau SY, Chen CY, Su YC, Wei JC. Traditional Chinese medicine in the treatment of patients with hyperuricemia: A randomized placebo-controlled double-blinded clinical trial. International journal of rheumatic diseases 2024. link 27 Zhang Y, Chen Y, Chen X, Gao Y, Luo J, Lu S et al.. Unconjugated bilirubin promotes uric acid restoration by activating hepatic AMPK pathway. Free radical biology & medicine 2024. link 28 Iwama R, Nishida K, Ishii D, Iijima T. An integrated population pharmacokinetic model of febuxostat in pediatric patients with hyperuricemia including gout and adult population of healthy subjects and patients with renal dysfunction. Pharmacology research & perspectives 2024. link 29 Zeng L, Ma P, Li Z, Liang S, Wu C, Hong C et al.. Multimodal Machine Learning-Based Marker Enables Early Detection and Prognosis Prediction for Hyperuricemia. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2024. link 30 Ren X, Cai Y, Zhang M, Hou Y, Wang J, Chen O. Association of weight-adjusted waist index with hyperuricemia and gout among middle-aged and older adults in America: a cross-sectional analysis of NHANES 2007-2014. Clinical rheumatology 2024. link 31 Fukui S, Okada M, Shinozaki T, Asano T, Nakai T, Tamaki H et al.. Changes in alcohol intake and serum urate changes: longitudinal analyses of annual medical examination database. Annals of the rheumatic diseases 2024. link 32 Wang Z, Li H, Sun L, Liu B, Gu X. Efficacy and safety of ultrafiltration combined with haemodialysis in patients with uraemia who cannot tolerate dialysis because of hypotension. Acta cardiologica 2024. link 33 Fajardo VC, Barreto SM, Coelho CG, Diniz MFH, Molina MDCB, Ribeiro ALP et al.. Adherence to the Dietary Approaches to Stop Hypertension (DASH) and Serum Urate Concentrations: A Longitudinal Analysis from the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). The Journal of nutrition 2024. link 34 Wani SK, Bhat MDA, Malik R. Efficacy of Aristolochia rotunda Linn in hyperuricemia: A randomised standard controlled study. Clinical nutrition ESPEN 2023. link 35 Chen Y, Luo L, Hu S, Gan R, Zeng L. The chemistry, processing, and preclinical anti-hyperuricemia potential of tea: a comprehensive review. Critical reviews in food science and nutrition 2023. link 36 Ding R, Deng X, Chen L, Zhen Y, Li X, Xiong T et al.. A dose-escalation study of HP501, a highly selective URAT1 inhibitor, in male Chinese patients with hyperuricemia. Scientific reports 2023. link 37 Li D, Yuan S, Deng Y, Wang X, Wu S, Chen X et al.. The dysregulation of immune cells induced by uric acid: mechanisms of inflammation associated with hyperuricemia and its complications. Frontiers in immunology 2023. link 38 Wu H, Wang Y, Li YL, Huang JJ, Lin ZJ, Zhang B. Current status and trends for natural products on hyperuricemia research: a scientometric visualization analysis from 2000 to 2021. European review for medical and pharmacological sciences 2023. link 39 Kohagura K, Kojima S, Uchiyama K, Yokota N, Tokutake E, Wakasa Y et al.. Febuxostat and renal outcomes: post-hoc analysis of a randomized trial. Hypertension research : official journal of the Japanese Society of Hypertension 2023. link 40 Yu LL, Li CN, Fang MY, Ma Y, Wang B, Lin FP et al.. Evaluating the effectiveness and safety of acupuncture on serum uric acid in asymptomatic hyperuricemia population: a randomized controlled clinical trial study protocol. Frontiers in endocrinology 2023. link 41 Wang C, Yu Q, Jiang X, Deng Y, Sun F, Li X et al.. A Drug-Drug Interaction Study of a Novel Selective Urate Reabsorption Inhibitor, SHR4640, and Xanthine Oxidase Inhibitor, Febuxostat, in Patients With Primary Hyperuricemia. Journal of clinical pharmacology 2023. link 42 Liu H, Xie R, Dai Q, Fang J, Xu Y, Li B. Exploring the mechanism underlying hyperuricemia using comprehensive research on multi-omics. Scientific reports 2023. link 43 Vreju AF, Pârvănescu CD, Turcu-Ştiolică A, Dinescu ŞC, Firulescu SC, Bărbulescu AL et al.. Time to redefine hyperuricemia? The serum uric acid cut-off level for precipitation might be lower: a pilot study. Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie 2023. link 44 Liu Y, Liu N, Bian W, Zhang Y, Wu Y, Peng Y et al.. Peptide NCTX15 derived from spider toxin gland effectively relieves hyperuricemia in mice. Biochemical and biophysical research communications 2023. link 45 Xie H, Hu N, Pan T, Wu JC, Yu M, Wang DC. Effectiveness and safety of different doses of febuxostat compared with allopurinol in the treatment of hyperuricemia: a meta-analysis of randomized controlled trials. BMC pharmacology & toxicology 2023. link 46 Koike R, Kawakami Y, Kondo R, Onishi M, Akiyama M, Asai T et al.. Effect of Dietary Counseling on Patients with Asymptomatic Hyperuricemia. The journal of medical investigation : JMI 2023. link 47 Hashimoto H, Takeuchi M, Kawakami K. Association between urate-lowering therapy and cardiovascular events in patients with asymptomatic hyperuricemia. Clinical rheumatology 2023. link 48 Sapankaew T, Thadanipon K, Ruenroengbun N, Chaiyakittisopon K, Ingsathit A, Numthavaj P et al.. Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials. BMC nephrology 2022. link 49 Gutierrez M, Sandoval H, Bertolazzi C, Soto-Fajardo C, Tellez-Gastelum RM, Reginato AM et al.. Update of the current role of ultrasound in asymptomatic hyperuricemia. A systematic literature review. Joint bone spine 2022. link 50 Wang Z, Li X, Jin Y, Liu R, Di X, Zhou Y et al.. Safety, Efficacy, and Pharmacokinetics of HP501 in Healthy Volunteers and Hyperuricemic Patients: A Phase I/IIa Study. The Journal of clinical endocrinology and metabolism 2022. link 51 Wang CC, Li YL, Chiu PY, Chen C, Chen HC, Chen FA. Protective effects of corni fructus extract in mice with potassium oxonate-induced hyperuricemia. The Journal of veterinary medical science 2022. link 52 Zhang Q, Li H, Xing D, Lin J. Global research trends in hyperuricemia: a bibliometric and visualized study. Modern rheumatology 2022. link 53 Yan J, Zhou Y, Yang Q, Wu J, He X. Evaluation of the safety and efficacy of a Fuling-Zexie decoction for people with asymptomatic hyperuricemia: protocol for a prospective, double-blinded, randomized, placebo-controlled clinical trial. Trials 2022. link 54 Lv Z, Cui J, Zhang J. Associations between serum urate and telomere length and inflammation markers: Evidence from UK Biobank cohort. Frontiers in immunology 2022. link 55 Zhang X, Mass BB, Talevi V, Hou R, North KE, Voruganti VS. Novel Insights into the Effects of Genetic Variants on Serum Urate Response to an Acute Fructose Challenge: A Pilot Study. Nutrients 2022. link 56 Yang Q, Zhang J, Li J. Clinical Effect of the Guizhi Shaoyao Zhimu Decoction in the Treatment of Hyperuricemia. BioMed research international 2022. link 57 Lee HJ, Choi JY, Lee J, Kim D, Min JY, Min KB. Association between serum uric acid and α-klotho protein levels in the middle-aged population. Aging 2022. link 58 Yao J, Zhang Y, Zhao J, Lin YP, Lu QY, Fan GJ. Correlation of obesity, dietary patterns, and blood pressure with uric acid: data from the NHANES 2017-2018. BMC endocrine disorders 2022. link 59 Yuan X, Chen R, Zhang Y, Lin X, Yang X. Altered Gut Microbiota in Children With Hyperuricemia. Frontiers in endocrinology 2022. link 60 Zhang Y, Yu H, Chai S, Chai X, Wang L, Geng WC et al.. Noninvasive and Individual-Centered Monitoring of Uric Acid for Precaution of Hyperuricemia via Optical Supramolecular Sensing. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2022. link 61 Bupparenoo P, Pakchotanon R, Narongroeknawin P, Asavatanabodee P, Chaiamnuay S. Effect of Curcumin on Serum Urate in Asymptomatic Hyperuricemia: A Randomized Placebo-Controlled Trial. Journal of dietary supplements 2021. link 62 Zhu C, Sun B, Zhang B, Zhou Z. An update of genetics, co-morbidities and management of hyperuricaemia. Clinical and experimental pharmacology & physiology 2021. link 63 Xu C, Wen J, Yang H, You Y, Zhan D, Yu J et al.. Factors Influencing Early Serum Uric Acid Fluctuation After Bariatric Surgery in Patients with Hyperuricemia. Obesity surgery 2021. link 64 Noori S, Mirzababaei A, Amini MR, Clark CCT, Mirzaei K. Effect of orlistat on serum uric acid level in adults: A systematic review and meta-analysis of randomised controlled trials. International journal of clinical practice 2021. link 65 Engel B, Hoffmann F, Freitag MH, Jacobs H. Should we be more aware of gender aspects in hyperuricemia? Analysis of the population-based German health interview and examination survey for adults (DEGS1). Maturitas 2021. link 66 Yang HJ, Liu M, Kim MJ, Park S. The haplotype of . International journal of food sciences and nutrition 2021. link 67 Fan N, Yu Y, Li L, Xia H, Dong X, Li Y et al.. Uricase deficiency causes mild and multiple organ injuries in rats. PloS one 2021. link 68 Mehmood A, Rehman AU, Ishaq M, Zhao L, Li J, Usman M et al.. (no title). Combinatorial chemistry & high throughput screening 2020. link 69 Huang J, Ma ZF, Zhang Y, Wan Z, Li Y, Zhou H et al.. Geographical distribution of hyperuricemia in mainland China: a comprehensive systematic review and meta-analysis. Global health research and policy 2020. link 70 Lin YJ, Lin SY, Lin CH, Wang ST, Chang SS. Evaluation of urate-lowering therapy in hyperuricemia patients: a systematic review and Bayesian network meta-analysis of randomized controlled trials. Clinical rheumatology 2020. link 71 Hosoya T, Sano T, Sasaki T, Fushimi M, Ohashi T. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study. Clinical and experimental nephrology 2020. link 72 Keenan RT. The biology of urate. Seminars in arthritis and rheumatism 2020. link 73 Brucato A, Cianci F, Carnovale C. Management of hyperuricemia in asymptomatic patients: A critical appraisal. European journal of internal medicine 2020. link 74 Hosoya T, Sano T, Sasaki T, Fushimi M, Ohashi T. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study. Clinical and experimental nephrology 2020. link 75 Isnuwardana R, Bijukchhe S, Thadanipon K, Ingsathit A, Thakkinstian A. Association Between Vitamin D and Uric Acid in Adults: A Systematic Review and Meta-Analysis. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2020. link 76 Chalès G. How should we manage asymptomatic hyperuricemia?. Joint bone spine 2019. link 77 Alqarni NA, Hassan AH. Knowledge and practice in the management of asymptomatic hyperuricemia among primary health care physicians in Jeddah, Western Region of Saudi Arabia. Saudi medical journal 2018. link 78 Gao Z, Lü K. Value and Progress of Ultrasound in Diagnosis and Treatment of Hyperuricemia. Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 2017. link 79 Chen RJ, Chen MH, Chen YL, Hsiao CM, Chen HM, Chen SJ et al.. Evaluating the urate-lowering effects of different microbial fermented extracts in hyperuricemic models accompanied with a safety study. Journal of food and drug analysis 2017. link 80 de Albuquerque Ugoline BC, de Souza J, Ferrari FC, Ferraz-Filha ZS, Coelho GB, Saúde-Guimarães DA. The influence of seasonality on the content of goyazensolide and on anti-inflammatory and anti-hyperuricemic effects of the ethanolic extract of Lychnophora passerina (Brazilian arnica). Journal of ethnopharmacology 2017. link 81 Qu LH, Jiang H, Chen JH. Effect of uric acid-lowering therapy on blood pressure: systematic review and meta-analysis. Annals of medicine 2017. link 82 Park KY, Kim HJ, Ahn HS, Kim SH, Park EJ, Yim SY et al.. Effects of coffee consumption on serum uric acid: systematic review and meta-analysis. Seminars in arthritis and rheumatism 2016. link 83 Li S, Yang H, Guo Y, Wei F, Yang X, Li D et al.. Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis. Scientific reports 2016. link 84 Larsen KS, Pottegård A, Lindegaard HM, Hallas J. Effect of Allopurinol on Cardiovascular Outcomes in Hyperuricemic Patients: A Cohort Study. The American journal of medicine 2016. link 85 Desideri G, Puig JG, Richette P. The management of hyperuricemia with urate deposition. Current medical research and opinion 2015. link 86 Zykova SN, Storhaug HM, Toft I, Chadban SJ, Jenssen TG, White SL. Cross-sectional analysis of nutrition and serum uric acid in two Caucasian cohorts: the AusDiab Study and the Tromsø study. Nutrition journal 2015. link 87 Allen KC, Champlain AH, Cotliar JA, Belknap SM, West DP, Mehta J et al.. Risk of anaphylaxis with repeated courses of rasburicase: a Research on Adverse Drug Events and Reports (RADAR) project. Drug safety 2015. link 88 Chen JH, Wen CP, Wu SB, Lan JL, Tsai MK, Tai YP et al.. Attenuating the mortality risk of high serum uric acid: the role of physical activity underused. Annals of the rheumatic diseases 2015. link 89 Stelmach MJ, Wasilewska N, Wicklund-Liland LI, Wasilewska A. Blood lipid profile and BMI-Z-score in adolescents with hyperuricemia. Irish journal of medical science 2015. link 90 Gosling AL, Matisoo-Smith E, Merriman TR. Hyperuricaemia in the Pacific: why the elevated serum urate levels?. Rheumatology international 2014. link 91 Kimura-Hayama E, Criales-Vera S, Nicolaou S, Betanzos JL, Rivera Y, Alberú J et al.. A pilot study on dual-energy computed tomography for detection of urate deposits in renal transplant patients with asymptomatic hyperuricemia. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2014. link 92 Krishnan E, Bennett M, Chen L. Aging, not menopause, is associated with higher prevalence of hyperuricemia among older women. Menopause (New York, N.Y.) 2014. link 93 Desideri G, Castaldo G, Lombardi A, Mussap M, Testa A, Pontremoli R et al.. Is it time to revise the normal range of serum uric acid levels?. European review for medical and pharmacological sciences 2014. link 94 Vinik O, Wechalekar MD, Falzon L, Buchbinder R, van der Heijde DM, Bombardier C. Treatment of asymptomatic hyperuricemia for the prevention of gouty arthritis, renal disease, and cardiovascular events: a systematic literature review. The Journal of rheumatology. Supplement 2014. link 95 Nakayama A, Matsuo H, Nakaoka H, Nakamura T, Nakashima H, Takada Y et al.. Common dysfunctional variants of ABCG2 have stronger impact on hyperuricemia progression than typical environmental risk factors. Scientific reports 2014. link 96 Katsiki N, Karagiannis A, Athyros VG, Mikhailidis DP. Hyperuricaemia: more than just a cause of gout?. Journal of cardiovascular medicine (Hagerstown, Md.) 2013. link 97 Hou CW, Lee YC, Hung HF, Fu HW, Jeng KC. Longan seed extract reduces hyperuricemia via modulating urate transporters and suppressing xanthine oxidase activity. The American journal of Chinese medicine 2012. link 98 Rodrigues SL, Baldo MP, Capingana P, Magalhães P, Dantas EM, Molina Mdel C et al.. Gender distribution of serum uric acid and cardiovascular risk factors: population based study. Arquivos brasileiros de cardiologia 2012. link 99 Alvarez-Lario B, Macarrón-Vicente J. Is there anything good in uric acid?. QJM : monthly journal of the Association of Physicians 2011. link 100 Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T et al.. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2011. link

Original source

[1]
Unraveling the heterogeneity of hyperuricemia using untargeted metabolomics and statistical modeling. — Wang J, Zeng Z, Duan W, Man Z, Wang M, Yang Z Journal of pharmaceutical and biomedical analysis (2026)
[2]
Targeting amino acid metabolic pathways: a novel therapeutic strategy for hyperuricemia-associated complications. — Zhang X, Wang W, Yang L, Sun Y, Sun H, Zhao X et al. Amino acids (2026)
[3]
Perceptions About Asymptomatic Hyperuricemia and Views About Urate-Lowering Therapy in People With Asymptomatic Hyperuricemia. — Dalbeth N, Stewart S, Gamble GD, Mihov B, Stamp LK, Haslett J et al. Arthritis care & research (2026)
[4]
Patients' knowledge influences practice via attitudes toward hyperuricaemia: a mediation analysis. — Shi H, Zhu Y, Guo Q, Li J, Lv T, Wu Y et al. Clinical rheumatology (2026)
[5]
Proteomic footprint of serum urate concentration and urate transporter — Ohashi Y, Ichihara S, Yamamoto K, Kitamura Y, Matsubara T, Beppo R et al. RMD open (2026)
[6]
Longitudinal Changes in Serum Urate Levels From Premenopause Through Postmenopause: Interrupted Time-Series Analyses. — Billa S, Fukui S, Paudel ML, Suzuki T, Imai R, Kim Y et al. Arthritis & rheumatology (Hoboken, N.J.) (2026)
[7]
The relationship between the atherogenic index of plasma and hyperuricemia in American adults aged over 20 years: A cross-sectional study. — She C, Shi L, Li Y, Qin L, Fang N, Shi K et al. PloS one (2026)
[8]
Reducing hyperuricemic events with SGLT2 inhibitors: An updated systematic review with meta-regression. — Ghukasyan H, Pedro Navalha DD, Pérez Romero I, Prato Wolwacz MV, Ghahramanyan A, Tsing Ngan CW et al. Endocrinologia, diabetes y nutricion (2025)
[9]
The human gut microbiota and uric acid metabolism: genes, metabolites, and diet. — Sun L, Zhang M, Zhao J, Chen W, Wang G Critical reviews in food science and nutrition (2025)
[10]
Bibliometric and visual assessment of research trends in the management of hyperuricemia (HUA). — Chen Y, Li G, Asghar A, Fang Q, Yang J, Zhong Y et al. Clinical rheumatology (2025)
[11]
Mechanisms Associated With Renal Injury in Hyperuricemia and Strategies for the Development of Natural Active Substances. — Lv W, Chen H, Zhou P, Du A, Lei Y International journal of rheumatic diseases (2025)
[12]
A Rapid Electrochemical DNA Biosensor for Serum Uric Acid Using the Pre-equilibrium Binding Mechanism. — Li Z, Gao G, Lv Y, Zhang Y, Wang H, Liu B Analytical chemistry (2025)
[13]
Febuxostat, a Urate-Lowering Drug Bridging From Adults to Pediatrics; A Brief Report. — Faghihi T, Assadi F Clinical therapeutics (2025)
[14]
Effects of thyroid-stimulating hormone and sensitivity to thyroid hormones on the risk of hyperuricemia in euthyroid adults. — Ding H, Liang Y, Wang Y, Zhang K, Zhu M, Jing Y et al. Archives of endocrinology and metabolism (2025)
[15]
Clinical outcomes and safety of Chinese herbal medicine in the treatment of hyperuricemia: A retrospective real-world study. — Long Z, Zhao H, Yin Y, Sun Y, Shen P, Lin H et al. Phytomedicine : international journal of phytotherapy and phytopharmacology (2025)
[16]
Weight Reduction and Target Serum Urate Level: A Longitudinal Study of Annual Medical Examination. — Fukui S, Okada M, Shinozaki T, Suzuki T, Nakai T, Ozawa H et al. Arthritis & rheumatology (Hoboken, N.J.) (2025)
[17]
Lipid accumulation product: A novel marker for gout and hyperuricemia. — Xian D, Wang W, Li H, Song G, Xu D, Zhang F et al. PloS one (2025)
[18]
Higher cardiometabolic index elevates the risk of hyperuricemia in the elderly: findings from the China health and retirement longitudinal study. — Zhong L, Li D, Xu F, Wu Y, Zhang Y Annals of medicine (2025)
[19]
Effects of WN1703 on Cardiovascular Function in Chronic Hyperuricemia Rats and Myocardial Injury Mechanism Exploration in H9C2 Cells. — Lu X, Liu F, Chen H, Cai H, Zhang L, Li J Journal of applied toxicology : JAT (2025)
[20]
Asymptomatic Hyperuricemia: A Nephro-Rheumatological Perspective. — Moszczuk B, Życińska K, Mucha K Archivum immunologiae et therapiae experimentalis (2024)
[21]
Exercise and hyperuricemia: an opinion article. — Zhang T, Liu W, Gao S Annals of medicine (2024)
[22]
Dissecting the risk factors for hyperuricemia in vegetarians in Taiwan. — Chang KC, Huang SY, Tsai WH, Liu HW, Liu JS, Wu CL et al. Journal of the Chinese Medical Association : JCMA (2024)
[23]
Cardiovascular safety of febuxostat versus allopurinol among the Asian patients with or without gout: A systematic review and meta-analysis. — Deng JH, Lai PH, Xie LS, Qiu SS, Qiu DS, Zhang JX Clinical and translational science (2024)
[24]
Data mining-guided alleviation of hyperuricemia by Paeonia veitchii Lynch through inhibition of xanthine oxidase and regulation of renal urate transporters. — Du J, Wang N, Yu D, He P, Gao Y, Tu Y et al. Phytomedicine : international journal of phytotherapy and phytopharmacology (2024)
[25]
Hyperuricemia and its related diseases: mechanisms and advances in therapy. — Du L, Zong Y, Li H, Wang Q, Xie L, Yang B et al. Signal transduction and targeted therapy (2024)
[26]
Traditional Chinese medicine in the treatment of patients with hyperuricemia: A randomized placebo-controlled double-blinded clinical trial. — Leong PY, Chen HH, Gau SY, Chen CY, Su YC, Wei JC International journal of rheumatic diseases (2024)
[27]
Unconjugated bilirubin promotes uric acid restoration by activating hepatic AMPK pathway. — Zhang Y, Chen Y, Chen X, Gao Y, Luo J, Lu S et al. Free radical biology & medicine (2024)
[28]
An integrated population pharmacokinetic model of febuxostat in pediatric patients with hyperuricemia including gout and adult population of healthy subjects and patients with renal dysfunction. — Iwama R, Nishida K, Ishii D, Iijima T Pharmacology research & perspectives (2024)
[29]
Multimodal Machine Learning-Based Marker Enables Early Detection and Prognosis Prediction for Hyperuricemia. — Zeng L, Ma P, Li Z, Liang S, Wu C, Hong C et al. Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2024)
[30]
Association of weight-adjusted waist index with hyperuricemia and gout among middle-aged and older adults in America: a cross-sectional analysis of NHANES 2007-2014. — Ren X, Cai Y, Zhang M, Hou Y, Wang J, Chen O Clinical rheumatology (2024)
[31]
Changes in alcohol intake and serum urate changes: longitudinal analyses of annual medical examination database. — Fukui S, Okada M, Shinozaki T, Asano T, Nakai T, Tamaki H et al. Annals of the rheumatic diseases (2024)
[32]
Efficacy and safety of ultrafiltration combined with haemodialysis in patients with uraemia who cannot tolerate dialysis because of hypotension. — Wang Z, Li H, Sun L, Liu B, Gu X Acta cardiologica (2024)
[33]
Adherence to the Dietary Approaches to Stop Hypertension (DASH) and Serum Urate Concentrations: A Longitudinal Analysis from the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). — Fajardo VC, Barreto SM, Coelho CG, Diniz MFH, Molina MDCB, Ribeiro ALP et al. The Journal of nutrition (2024)
[34]
Efficacy of Aristolochia rotunda Linn in hyperuricemia: A randomised standard controlled study. — Wani SK, Bhat MDA, Malik R Clinical nutrition ESPEN (2023)
[35]
The chemistry, processing, and preclinical anti-hyperuricemia potential of tea: a comprehensive review. — Chen Y, Luo L, Hu S, Gan R, Zeng L Critical reviews in food science and nutrition (2023)
[36]
A dose-escalation study of HP501, a highly selective URAT1 inhibitor, in male Chinese patients with hyperuricemia. — Ding R, Deng X, Chen L, Zhen Y, Li X, Xiong T et al. Scientific reports (2023)
[37]
The dysregulation of immune cells induced by uric acid: mechanisms of inflammation associated with hyperuricemia and its complications. — Li D, Yuan S, Deng Y, Wang X, Wu S, Chen X et al. Frontiers in immunology (2023)
[38]
Current status and trends for natural products on hyperuricemia research: a scientometric visualization analysis from 2000 to 2021. — Wu H, Wang Y, Li YL, Huang JJ, Lin ZJ, Zhang B European review for medical and pharmacological sciences (2023)
[39]
Febuxostat and renal outcomes: post-hoc analysis of a randomized trial. — Kohagura K, Kojima S, Uchiyama K, Yokota N, Tokutake E, Wakasa Y et al. Hypertension research : official journal of the Japanese Society of Hypertension (2023)
[40]
Evaluating the effectiveness and safety of acupuncture on serum uric acid in asymptomatic hyperuricemia population: a randomized controlled clinical trial study protocol. — Yu LL, Li CN, Fang MY, Ma Y, Wang B, Lin FP et al. Frontiers in endocrinology (2023)
[41]
A Drug-Drug Interaction Study of a Novel Selective Urate Reabsorption Inhibitor, SHR4640, and Xanthine Oxidase Inhibitor, Febuxostat, in Patients With Primary Hyperuricemia. — Wang C, Yu Q, Jiang X, Deng Y, Sun F, Li X et al. Journal of clinical pharmacology (2023)
[42]
Exploring the mechanism underlying hyperuricemia using comprehensive research on multi-omics. — Liu H, Xie R, Dai Q, Fang J, Xu Y, Li B Scientific reports (2023)
[43]
Time to redefine hyperuricemia? The serum uric acid cut-off level for precipitation might be lower: a pilot study. — Vreju AF, Pârvănescu CD, Turcu-Ştiolică A, Dinescu ŞC, Firulescu SC, Bărbulescu AL et al. Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie (2023)
[44]
Peptide NCTX15 derived from spider toxin gland effectively relieves hyperuricemia in mice. — Liu Y, Liu N, Bian W, Zhang Y, Wu Y, Peng Y et al. Biochemical and biophysical research communications (2023)
[45]
Effectiveness and safety of different doses of febuxostat compared with allopurinol in the treatment of hyperuricemia: a meta-analysis of randomized controlled trials. — Xie H, Hu N, Pan T, Wu JC, Yu M, Wang DC BMC pharmacology & toxicology (2023)
[46]
Effect of Dietary Counseling on Patients with Asymptomatic Hyperuricemia. — Koike R, Kawakami Y, Kondo R, Onishi M, Akiyama M, Asai T et al. The journal of medical investigation : JMI (2023)
[47]
Association between urate-lowering therapy and cardiovascular events in patients with asymptomatic hyperuricemia. — Hashimoto H, Takeuchi M, Kawakami K Clinical rheumatology (2023)
[48]
Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials. — Sapankaew T, Thadanipon K, Ruenroengbun N, Chaiyakittisopon K, Ingsathit A, Numthavaj P et al. BMC nephrology (2022)
[49]
Update of the current role of ultrasound in asymptomatic hyperuricemia. A systematic literature review. — Gutierrez M, Sandoval H, Bertolazzi C, Soto-Fajardo C, Tellez-Gastelum RM, Reginato AM et al. Joint bone spine (2022)
[50]
Safety, Efficacy, and Pharmacokinetics of HP501 in Healthy Volunteers and Hyperuricemic Patients: A Phase I/IIa Study. — Wang Z, Li X, Jin Y, Liu R, Di X, Zhou Y et al. The Journal of clinical endocrinology and metabolism (2022)
[51]
Protective effects of corni fructus extract in mice with potassium oxonate-induced hyperuricemia. — Wang CC, Li YL, Chiu PY, Chen C, Chen HC, Chen FA The Journal of veterinary medical science (2022)
[52]
Global research trends in hyperuricemia: a bibliometric and visualized study. — Zhang Q, Li H, Xing D, Lin J Modern rheumatology (2022)
[53]
Evaluation of the safety and efficacy of a Fuling-Zexie decoction for people with asymptomatic hyperuricemia: protocol for a prospective, double-blinded, randomized, placebo-controlled clinical trial. — Yan J, Zhou Y, Yang Q, Wu J, He X Trials (2022)
[54]
Associations between serum urate and telomere length and inflammation markers: Evidence from UK Biobank cohort. — Lv Z, Cui J, Zhang J Frontiers in immunology (2022)
[55]
Novel Insights into the Effects of Genetic Variants on Serum Urate Response to an Acute Fructose Challenge: A Pilot Study. — Zhang X, Mass BB, Talevi V, Hou R, North KE, Voruganti VS Nutrients (2022)
[56]
Clinical Effect of the Guizhi Shaoyao Zhimu Decoction in the Treatment of Hyperuricemia. — Yang Q, Zhang J, Li J BioMed research international (2022)
[57]
Association between serum uric acid and α-klotho protein levels in the middle-aged population. — Lee HJ, Choi JY, Lee J, Kim D, Min JY, Min KB Aging (2022)
[58]
Correlation of obesity, dietary patterns, and blood pressure with uric acid: data from the NHANES 2017-2018. — Yao J, Zhang Y, Zhao J, Lin YP, Lu QY, Fan GJ BMC endocrine disorders (2022)
[59]
Altered Gut Microbiota in Children With Hyperuricemia. — Yuan X, Chen R, Zhang Y, Lin X, Yang X Frontiers in endocrinology (2022)
[60]
Noninvasive and Individual-Centered Monitoring of Uric Acid for Precaution of Hyperuricemia via Optical Supramolecular Sensing. — Zhang Y, Yu H, Chai S, Chai X, Wang L, Geng WC et al. Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2022)
[61]
Effect of Curcumin on Serum Urate in Asymptomatic Hyperuricemia: A Randomized Placebo-Controlled Trial. — Bupparenoo P, Pakchotanon R, Narongroeknawin P, Asavatanabodee P, Chaiamnuay S Journal of dietary supplements (2021)
[62]
An update of genetics, co-morbidities and management of hyperuricaemia. — Zhu C, Sun B, Zhang B, Zhou Z Clinical and experimental pharmacology & physiology (2021)
[63]
Factors Influencing Early Serum Uric Acid Fluctuation After Bariatric Surgery in Patients with Hyperuricemia. — Xu C, Wen J, Yang H, You Y, Zhan D, Yu J et al. Obesity surgery (2021)
[64]
Effect of orlistat on serum uric acid level in adults: A systematic review and meta-analysis of randomised controlled trials. — Noori S, Mirzababaei A, Amini MR, Clark CCT, Mirzaei K International journal of clinical practice (2021)
[65]
Should we be more aware of gender aspects in hyperuricemia? Analysis of the population-based German health interview and examination survey for adults (DEGS1). — Engel B, Hoffmann F, Freitag MH, Jacobs H Maturitas (2021)
[66]
The haplotype of — Yang HJ, Liu M, Kim MJ, Park S International journal of food sciences and nutrition (2021)
[67]
Uricase deficiency causes mild and multiple organ injuries in rats. — Fan N, Yu Y, Li L, Xia H, Dong X, Li Y et al. PloS one (2021)
[68]
(no title) — Mehmood A, Rehman AU, Ishaq M, Zhao L, Li J, Usman M et al. Combinatorial chemistry & high throughput screening (2020)
[69]
Geographical distribution of hyperuricemia in mainland China: a comprehensive systematic review and meta-analysis. — Huang J, Ma ZF, Zhang Y, Wan Z, Li Y, Zhou H et al. Global health research and policy (2020)
[70]
Evaluation of urate-lowering therapy in hyperuricemia patients: a systematic review and Bayesian network meta-analysis of randomized controlled trials. — Lin YJ, Lin SY, Lin CH, Wang ST, Chang SS Clinical rheumatology (2020)
[71]
Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study. — Hosoya T, Sano T, Sasaki T, Fushimi M, Ohashi T Clinical and experimental nephrology (2020)
[72]
The biology of urate. — Keenan RT Seminars in arthritis and rheumatism (2020)
[73]
Management of hyperuricemia in asymptomatic patients: A critical appraisal. — Brucato A, Cianci F, Carnovale C European journal of internal medicine (2020)
[74]
Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study. — Hosoya T, Sano T, Sasaki T, Fushimi M, Ohashi T Clinical and experimental nephrology (2020)
[75]
Association Between Vitamin D and Uric Acid in Adults: A Systematic Review and Meta-Analysis. — Isnuwardana R, Bijukchhe S, Thadanipon K, Ingsathit A, Thakkinstian A Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme (2020)
[76]
How should we manage asymptomatic hyperuricemia? — Chalès G Joint bone spine (2019)
[77]
Knowledge and practice in the management of asymptomatic hyperuricemia among primary health care physicians in Jeddah, Western Region of Saudi Arabia. — Alqarni NA, Hassan AH Saudi medical journal (2018)
[78]
Value and Progress of Ultrasound in Diagnosis and Treatment of Hyperuricemia. — Gao Z, Lü K Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae (2017)
[79]
Evaluating the urate-lowering effects of different microbial fermented extracts in hyperuricemic models accompanied with a safety study. — Chen RJ, Chen MH, Chen YL, Hsiao CM, Chen HM, Chen SJ et al. Journal of food and drug analysis (2017)
[80]
The influence of seasonality on the content of goyazensolide and on anti-inflammatory and anti-hyperuricemic effects of the ethanolic extract of Lychnophora passerina (Brazilian arnica). — de Albuquerque Ugoline BC, de Souza J, Ferrari FC, Ferraz-Filha ZS, Coelho GB, Saúde-Guimarães DA Journal of ethnopharmacology (2017)
[81]
Effect of uric acid-lowering therapy on blood pressure: systematic review and meta-analysis. — Qu LH, Jiang H, Chen JH Annals of medicine (2017)
[82]
Effects of coffee consumption on serum uric acid: systematic review and meta-analysis. — Park KY, Kim HJ, Ahn HS, Kim SH, Park EJ, Yim SY et al. Seminars in arthritis and rheumatism (2016)
[83]
Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis. — Li S, Yang H, Guo Y, Wei F, Yang X, Li D et al. Scientific reports (2016)
[84]
Effect of Allopurinol on Cardiovascular Outcomes in Hyperuricemic Patients: A Cohort Study. — Larsen KS, Pottegård A, Lindegaard HM, Hallas J The American journal of medicine (2016)
[85]
The management of hyperuricemia with urate deposition. — Desideri G, Puig JG, Richette P Current medical research and opinion (2015)
[86]
Cross-sectional analysis of nutrition and serum uric acid in two Caucasian cohorts: the AusDiab Study and the Tromsø study. — Zykova SN, Storhaug HM, Toft I, Chadban SJ, Jenssen TG, White SL Nutrition journal (2015)
[87]
Risk of anaphylaxis with repeated courses of rasburicase: a Research on Adverse Drug Events and Reports (RADAR) project. — Allen KC, Champlain AH, Cotliar JA, Belknap SM, West DP, Mehta J et al. Drug safety (2015)
[88]
Attenuating the mortality risk of high serum uric acid: the role of physical activity underused. — Chen JH, Wen CP, Wu SB, Lan JL, Tsai MK, Tai YP et al. Annals of the rheumatic diseases (2015)
[89]
Blood lipid profile and BMI-Z-score in adolescents with hyperuricemia. — Stelmach MJ, Wasilewska N, Wicklund-Liland LI, Wasilewska A Irish journal of medical science (2015)
[90]
Hyperuricaemia in the Pacific: why the elevated serum urate levels? — Gosling AL, Matisoo-Smith E, Merriman TR Rheumatology international (2014)
[91]
A pilot study on dual-energy computed tomography for detection of urate deposits in renal transplant patients with asymptomatic hyperuricemia. — Kimura-Hayama E, Criales-Vera S, Nicolaou S, Betanzos JL, Rivera Y, Alberú J et al. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases (2014)
[92]
Aging, not menopause, is associated with higher prevalence of hyperuricemia among older women. — Krishnan E, Bennett M, Chen L Menopause (New York, N.Y.) (2014)
[93]
Is it time to revise the normal range of serum uric acid levels? — Desideri G, Castaldo G, Lombardi A, Mussap M, Testa A, Pontremoli R et al. European review for medical and pharmacological sciences (2014)
[94]
Treatment of asymptomatic hyperuricemia for the prevention of gouty arthritis, renal disease, and cardiovascular events: a systematic literature review. — Vinik O, Wechalekar MD, Falzon L, Buchbinder R, van der Heijde DM, Bombardier C The Journal of rheumatology. Supplement (2014)
[95]
Common dysfunctional variants of ABCG2 have stronger impact on hyperuricemia progression than typical environmental risk factors. — Nakayama A, Matsuo H, Nakaoka H, Nakamura T, Nakashima H, Takada Y et al. Scientific reports (2014)
[96]
Hyperuricaemia: more than just a cause of gout? — Katsiki N, Karagiannis A, Athyros VG, Mikhailidis DP Journal of cardiovascular medicine (Hagerstown, Md.) (2013)
[97]
Longan seed extract reduces hyperuricemia via modulating urate transporters and suppressing xanthine oxidase activity. — Hou CW, Lee YC, Hung HF, Fu HW, Jeng KC The American journal of Chinese medicine (2012)
[98]
Gender distribution of serum uric acid and cardiovascular risk factors: population based study. — Rodrigues SL, Baldo MP, Capingana P, Magalhães P, Dantas EM, Molina Mdel C et al. Arquivos brasileiros de cardiologia (2012)
[99]
Is there anything good in uric acid? — Alvarez-Lario B, Macarrón-Vicente J QJM : monthly journal of the Association of Physicians (2011)
[100]
Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study. — Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T et al. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases (2011)

Share:Twitter Reddit LinkedIn